HRP20130194T1 - Imunosupresivni polipeptidi i nukleinske kiseline - Google Patents
Imunosupresivni polipeptidi i nukleinske kiseline Download PDFInfo
- Publication number
- HRP20130194T1 HRP20130194T1 HRP20130194AT HRP20130194T HRP20130194T1 HR P20130194 T1 HRP20130194 T1 HR P20130194T1 HR P20130194A T HRP20130194A T HR P20130194AT HR P20130194 T HRP20130194 T HR P20130194T HR P20130194 T1 HRP20130194 T1 HR P20130194T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- fusion protein
- dimeric
- seq
- lea29y
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 42
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 42
- 102000039446 nucleic acids Human genes 0.000 title claims 7
- 108020004707 nucleic acids Proteins 0.000 title claims 7
- 150000007523 nucleic acids Chemical class 0.000 title claims 7
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 claims 32
- 108020001507 fusion proteins Proteins 0.000 claims 32
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000054189 human CD80 Human genes 0.000 claims 1
- 102000049849 human CD86 Human genes 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (18)
1. Izolirani ili rekombinantni polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka i koja uključuje ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 i 106 koji su identični sa aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36, naznačen time da polipeptid veže humani CD80 ili humani CD86 ili izvanstaničnu domenu bilo kojeg od njih i ima sposobnost inhibicije imunološkog odgovora koja je veća od sposobnosti inhibicije imunološkog odgovora polipeptida LEA29Y koji sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
2. Polipeptid prema zahtjevu 1, naznačen time da se polipeptid razlikuje od SEQ ID NO:36 u ne više od 1, 2, 3, 4, ili 5 aminokiselinskih ostataka.
3. Polipeptid prema zahtjevu 1, naznačen time da polipeptid sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:36.
4. Izolirani ili rekombinantni dimerni polipeptid koji sadrži dva polipeptida prema bilo kojem od zahtjeva 1-3, naznačen time da dimer ima veću sposobnost za suzbijanje imunološkog odgovora nego dimer koji sadrži dva polipeptida LEA29Y, pri čemu svaki polipeptid LEA29Y sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
5. Polipeptid prema zahtjevu 1, koji je izolirani ili rekombinantni fuzijski protein naznačen time da sadrži (a) polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka i sadrži ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 i 106 koji su identični aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36 i (b) drugi polipeptid, pri čemu je drugi polipeptid Ig Fc polipeptid, te pri čemu fuzijski protein ima veću sposobnost za suzbijanje imunološkog odgovora nego LEA29Y-Ig fuzijski protein, pri čemu LEA29Y-Ig fuzijski protein sadrži polipeptidnu sekvencu prema SEQ ID NO:166.
6. Fuzijski protein prema zahtjevu 5, naznačen time da fuzijski protein sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:197 ili 211.
7. Dimerni polipeptid prema zahtjevu 4, koji je izolirani ili rekombinantni dimerni fuzijski protein koji sadrži dva monomerna fuzijska proteina povezana preko barem jedne disulfidne veze koja je formirana između dva cisteinska ostatka koji se nalaze u svakom monomernom mutiranom fuzijskom proteinu, naznačen time da svaki monomerni fuzijski protein sadrži (a) polipeptid sa polipeptidnom sekvencom koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka i koja sadrži ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 i 106 koji su identični aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36 i (b) Ig Fc polipeptid, pri čemu dimerni fuzijski protein ima veću sposobnost za suzbijanje imunološkog odgovora nego dimerni fuzijski protein LEA29Y-Ig, pri čemu dimerni fuzijski protein LEA29Y-Ig sadrži dva monomerna fuzijska proteina LEA29Y-Ig koji svaki sadrži polipeptidnu sekvencu prema SEQ ID NO:166.
8. Dimerni fuzijski protein prema zahtjevu 7, naznačen time da svaki monomerni fuzijski protein sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:197 ili 211.
9. Izolirana ili rekombinantna nukleinska kiselina naznačena time da sadrži polinukleotidnu sekvencu koja kodira polipeptid prema bilo kojem od zahtjeva 1-3, dimerni polipeptid prema zahtjevu 4, fuzijski protein prema zahtjevu 5 ili zahtjevu 6, ili dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8, ili njihovu komplementarnu polinukleotidnu sekvencu.
10. Vektor naznačen time da sadrži nukleinsku kiselinu prema zahtjevu 9.
11. Izolirana ili rekombinantna stanica domaćin naznačena time da sadrži:
(a) polipeptid prema bilo kojem od zahtjeva 1-3;
(b) dimerni polipeptid prema zahtjevu 4;
(c) fuzijski protein prema zahtjevu 5 ili zahtjevu 6;
(d) dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8;
(e) nukleinsku kiselinu prema zahtjevu 9; i/ili
(f) vektor prema zahtjevu 10.
12. Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljivu pomoćnu tvar ili farmaceutski prihvatljiv nosač i jedno ili više od slijedećeg:
(a) polipeptid prema bilo kojem od zahtjeva 1-3;
(b) dimerni polipeptid prema zahtjevu 4;
(c) fuzijski protein prema zahtjevu 5 ili zahtjevu 6;
(d) dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8;
(e) nukleinsku kiselinu prema zahtjevu 9;
(f) vektor prema zahtjevu 10; i/ili
(g) stanicu domaćina prema zahtjevu 11.
13. Farmaceutski pripravak prema zahtjevu 12, naznačen time da sadrži farmaceutski prihvatljivu pomoćnu tvar ili farmaceutski prihvatljiv nosač i dimerni fuzijski protein prema zahtjevu 8.
14. Polipeptid prema bilo kojem od zahtjeva 1-3, dimerni polipeptid prema zahtjevu 4, fuzijski protein prema zahtjevu 5 ili zahtjevu 6, dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8, nukleinska kiselina prema zahtjevu 9, vektor prema zahtjevu 10, ili stanica prema zahtjevu 11, naznačeni time da su za uporabu za:
(i) profilaktičko ili terapijsko liječenje za sprečavanje ili suzbijanje imunološkog odgovora kod sisavca;
(ii) liječenje bolesti ili poremećaja imunološkog sustava; ili
(iii) sprječavanje odbacivanja transplantiranog tkiva ili organa kod sisavca.
15. Dimerni fuzijski protein za uporabu prema zahtjevu 14, naznačen time da dimerni fuzijski protein je dimerni fuzijski protein prema zahtjevu 8.
16. Uporaba polipeptida prema bilo kojem od zahtjeva 1-3, dimernog polipeptida prema zahtjevu 4, fuzijskog proteina prema zahtjevu 5 ili zahtjevu 6, dimernog fuzijskog proteina prema zahtjevu 7 ili zahtjevu 8, nukleinske kiseline prema zahtjevu 9, vektora prema zahtjevu 10, ili stanice prema zahtjevu 11 naznačena time da se koristi za proizvodnju lijeka za:
(i) profilaktičko ili terapijsko liječenje za sprečavanje ili suzbijanje imunološkog odgovora kod sisavca;
(ii) liječenje bolesti ili poremećaja imunološkog sustava; ili
(iii) sprječavanje odbacivanja transplantiranog tkiva ili organa kod sisavca.
17. Uporaba dimernog fuzijskog proteina prema zahtjevu 16, naznačena time da dimerni fuzijski protein je dimerni fuzijski protein prema zahtjevu 8.
18. Postupak za dobivanje polipeptida naznačen time da sadrži kultiviranje stanice domaćina prema zahtjevu 11 u kultivacijskom mediju i izolacije polipeptida koji je stanica eksprimirala.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98463107P | 2007-11-01 | 2007-11-01 | |
US5121508P | 2008-05-07 | 2008-05-07 | |
PCT/US2008/079981 WO2009058564A2 (en) | 2007-11-01 | 2008-10-15 | Immunosuppressive polypeptides and nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20130194T1 true HRP20130194T1 (hr) | 2013-04-30 |
Family
ID=40124836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130194AT HRP20130194T1 (hr) | 2007-11-01 | 2013-03-05 | Imunosupresivni polipeptidi i nukleinske kiseline |
Country Status (20)
Country | Link |
---|---|
US (8) | US7794718B2 (hr) |
EP (4) | EP2385065A1 (hr) |
JP (1) | JP5298134B2 (hr) |
KR (1) | KR101383476B1 (hr) |
CN (2) | CN101998965B (hr) |
AU (1) | AU2008319053B2 (hr) |
CA (1) | CA2703263C (hr) |
CY (1) | CY1113713T1 (hr) |
DK (1) | DK2222697T3 (hr) |
ES (2) | ES2399088T3 (hr) |
HR (1) | HRP20130194T1 (hr) |
IL (1) | IL205036A (hr) |
MX (1) | MX2010004883A (hr) |
PH (1) | PH12013501101A1 (hr) |
PL (2) | PL2612868T3 (hr) |
PT (2) | PT2612868T (hr) |
RU (1) | RU2506275C2 (hr) |
TW (1) | TWI448473B (hr) |
WO (1) | WO2009058564A2 (hr) |
ZA (1) | ZA201002872B (hr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
EP1817340B1 (en) | 2004-11-12 | 2012-05-16 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP3409687A1 (en) | 2007-06-01 | 2018-12-05 | University of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
RU2506275C2 (ru) | 2007-11-01 | 2014-02-10 | Астеллас Фарма Инк. | Иммуносупрессорные полипептиды и нуклеиновые кислоты |
NZ603812A (en) * | 2007-11-20 | 2014-06-27 | Ambrx Inc | Modified insulin polypeptides and their uses |
PL2344540T3 (pl) | 2008-10-02 | 2018-05-30 | Aptevo Research And Development Llc | Białka wiążące wiele celów antagonistyczne względem cd86 |
JP5926680B2 (ja) * | 2009-07-28 | 2016-05-25 | リガセプト・エルエルシー | 広範囲のErbBリガンド結合分子ならびにそれを調製および使用するための方法 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
KR101193940B1 (ko) * | 2009-12-14 | 2012-10-24 | 고려대학교 산학협력단 | 레서스 원숭이 ctla-4 융합 이뮤노글로불린 |
SI2536745T1 (sl) | 2010-02-19 | 2016-10-28 | Xencor Inc. | Novi imunoadhezini CTLA4-Ig |
CN102822198B (zh) * | 2010-03-12 | 2016-08-31 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
CN103154034B (zh) | 2010-04-13 | 2016-06-08 | 塞尔德克斯医疗公司 | 结合人cd27的抗体及其用途 |
US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
KR20200111213A (ko) | 2010-07-28 | 2020-09-28 | 글리크닉 인코포레이티드 | 순차적으로 다중화된 면역글로불린 fc 조성물을 제조하기 위한 천연 인간 단백질 단편들의 융합 단백질 |
CA2826286C (en) * | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
RU2013143149A (ru) * | 2011-02-24 | 2015-03-27 | Пэксвэкс, Инк. | Составы, пригодные для вакцин, получаемых сушкой распылением |
WO2012159075A1 (en) * | 2011-05-19 | 2012-11-22 | Seattle Biomedical Research Institute | Bioprobe compositions and their methods of use |
CN102391377B (zh) * | 2011-11-01 | 2013-11-06 | 孙嘉琳 | 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途 |
CN102382193B (zh) * | 2011-11-01 | 2013-08-14 | 孙嘉琳 | 诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途 |
CN102516392B (zh) * | 2011-11-25 | 2014-05-28 | 孙嘉琳 | 一种癌靶向超抗原融合蛋白及制备方法及用途 |
WO2013112986A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
BR112014026718B1 (pt) | 2012-05-11 | 2021-05-18 | Medimmune Limited. | polipeptídeo isolado de ctla-4, célula hospedeira, composição e uso de um polipeptídeo ctla-4 |
US20160194660A1 (en) * | 2012-12-21 | 2016-07-07 | Merck Sharp & Dohme Corp. | Expression vectors for recombinant protein production in mammalian cells |
US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
CN104277112B (zh) * | 2013-07-04 | 2018-01-26 | 嘉和生物药业有限公司 | 长效降血糖融合蛋白 |
US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
US11340235B2 (en) | 2014-02-28 | 2022-05-24 | Ga Generic Assays Gmbh | GP2 isoforms and their use in autoantibody capture |
CN103923934B (zh) * | 2014-03-22 | 2016-11-02 | 复旦大学 | 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用 |
AU2015292590B2 (en) | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
NZ733025A (en) | 2014-12-12 | 2022-01-28 | 2Seventy Bio Inc | Bcma chimeric antigen receptors |
US11319359B2 (en) | 2015-04-17 | 2022-05-03 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
KR102582560B1 (ko) * | 2015-04-28 | 2023-09-26 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 아나킨라를 포함하는 조성물 |
EP3313875A4 (en) * | 2015-06-24 | 2018-12-26 | Board of Regents of the University of Texas System | Methods and compositions for treatment of symptoms associated with intracranial hemorrhage |
US11053295B2 (en) | 2015-08-21 | 2021-07-06 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Peptides having effects of preventing or treating central nervous system diseases and pharmaceutical compositions for preventing or treating central nervous system diseases containing same as active ingredient |
WO2017034244A1 (ko) * | 2015-08-21 | 2017-03-02 | 한양대학교 산학협력단 | 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물 |
US11351224B2 (en) | 2015-08-21 | 2022-06-07 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Pharmaceutical composition for preventing and treating transplant rejection |
CN108431045B (zh) * | 2015-09-01 | 2022-05-13 | 免疫功坊股份有限公司 | 用以预防血栓形成及/或治疗血栓的分子构建体 |
BR112018008865A8 (pt) * | 2015-11-02 | 2019-02-26 | Five Prime Therapeutics Inc | polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer |
KR20190006495A (ko) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
AU2017279538A1 (en) | 2016-06-07 | 2019-01-03 | Gliknik Inc. | Cysteine-optimized stradomers |
WO2017214834A1 (zh) * | 2016-06-14 | 2017-12-21 | 石庆学 | 特异促进 ctla-4 基因高表达的慢病毒表达载体及其应用 |
WO2018041121A1 (en) * | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ctla-4 |
CN107815468B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
TW201835098A (zh) | 2016-12-09 | 2018-10-01 | 美商吉林尼克公司 | 製備最佳化之多聚化斯塔都聚體(stradomer) gl-2045 |
KR20190139216A (ko) * | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
KR20230020022A (ko) | 2017-10-10 | 2023-02-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
KR20200085777A (ko) | 2017-10-18 | 2020-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법 |
KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
CN112543644A (zh) * | 2018-07-24 | 2021-03-23 | 古德T细胞有限公司 | 一种预防和治疗免疫相关疾病的组合物 |
EP3843767A1 (en) * | 2018-08-29 | 2021-07-07 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain fc fusion protein dosing regimens |
WO2020088645A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
EP3948281A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Spr-based binding assay for the functional analysis of multivalent molecules |
US11155609B2 (en) | 2019-04-05 | 2021-10-26 | TauC3 Biologies Limited | Anti-TAUC3 antibodies and uses thereof |
JP7405361B2 (ja) * | 2019-10-21 | 2023-12-26 | 東亞合成株式会社 | 抗腫瘍ペプチドおよびその利用 |
RU2760578C2 (ru) * | 2019-12-25 | 2021-11-29 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Слитый белок, содержащий модифицированный безметиониновый белок GroEL и димер полипептида полифемузина I |
CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
KR20230152085A (ko) * | 2021-02-23 | 2023-11-02 | 유니버시티 오브 워싱톤 | 심근 세포 이식을 위한 조성물 및 방법 |
CN117222667A (zh) * | 2021-03-16 | 2023-12-12 | Jn生物科学有限责任公司 | 用于治疗免疫失调的双功能分子 |
WO2022219185A1 (en) | 2021-04-16 | 2022-10-20 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
WO2023021050A1 (en) | 2021-08-17 | 2023-02-23 | Athebio Ag | Variants of ankyrin repeat domains |
EP4137508A1 (en) | 2021-08-17 | 2023-02-22 | Athebio AG | Variants of ankyrin repeat domains |
WO2023244760A1 (en) * | 2022-06-15 | 2023-12-21 | Duke University | Protein library display systems and methods thereof |
WO2024037743A1 (en) | 2022-08-16 | 2024-02-22 | Athebio Ag | Variants of ankyrin repeat domains |
WO2023194628A2 (en) | 2022-08-16 | 2023-10-12 | Athebio Ag | Variants of ankyrin repeat domains |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US511A (en) * | 1837-12-15 | Improved mode of coloring and finishing leather | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
IN151589B (hr) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
CA1200773A (en) | 1980-02-29 | 1986-02-18 | William J. Rutter | Expression linkers |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
JPS60188070A (ja) | 1984-03-09 | 1985-09-25 | Kunio Yamane | シグナルペプチドをコードするdna |
GB8412517D0 (en) | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
CA1341423C (en) | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
KR890003620Y1 (ko) | 1985-07-25 | 1989-05-27 | 삼성전자주식회사 | 전자레인지의 파워릴레이 구동회로 |
CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5084384A (en) | 1987-04-23 | 1992-01-28 | Monsanto Company | Secretion of insulin-like growth factor-I |
US6093699A (en) | 1987-07-09 | 2000-07-25 | The University Of Manitoba | Method for gene therapy involving suppression of an immune response |
US5017478A (en) | 1987-07-16 | 1991-05-21 | Berlex Laboratories, Inc. | Transfected cells containing plasmids having genes oriented in opposing directions and methods of using |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
US6710169B2 (en) * | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
ZA887365B (en) | 1987-10-02 | 1990-05-30 | Genentech Inc | Adheson variants |
US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
EP0325224B1 (en) * | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
US5284768A (en) | 1988-08-24 | 1994-02-08 | Sanofi | Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
DE3901681A1 (de) | 1989-01-21 | 1990-07-26 | Behringwerke Ag | Signalpeptid fuer die sekretion von peptiden in escherichia coli, verfahren zu seiner gewinnung und seine verwendung |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6406697B1 (en) * | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
CA2067821A1 (en) | 1989-10-24 | 1991-04-25 | Cetus Oncology Corporation | Infective drug delivery system using recombinant retroviral vectors |
ATE157012T1 (de) | 1989-11-03 | 1997-09-15 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
US7070776B1 (en) * | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
CA2106474C (en) | 1991-03-19 | 2004-02-10 | R. Martin Emanuele | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
AU661854B2 (en) * | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5506098A (en) | 1991-09-04 | 1996-04-09 | Daikin Industries, Ltd. | In situ hybridization method |
US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
EP0637963B1 (en) | 1992-04-07 | 2004-08-04 | The Regents of the University of Michigan | Cd28 pathway immunoregulation |
US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
EP0621337A1 (en) | 1993-01-25 | 1994-10-26 | American Cyanamid Company | Codon optimized DNA sequence for insect toxin AaIT |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US6482919B2 (en) * | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
WO1994021680A1 (en) | 1993-03-17 | 1994-09-29 | The Government Of The United States Of America As | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
EP1231277A2 (fr) | 1993-04-21 | 2002-08-14 | Institut Pasteur | Implant biocompatible pour la formation in vivo d'un neo-organe |
US5591601A (en) | 1993-05-14 | 1997-01-07 | Ohio University Edison Animal Biotechnology Institute | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system |
US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
EP0982405B1 (en) | 1993-09-15 | 2009-08-26 | Novartis Vaccines and Diagnostics, Inc. | Recombinant alphavirus vectors |
US6107095A (en) | 1993-11-26 | 2000-08-22 | Mazurkiewicz; Marian | Method for introducing substances into living cells and tissues |
US5580766A (en) | 1994-01-14 | 1996-12-03 | Alexion Pharmaceuticals, Inc. | Retroviral vector particles for transducing non-proliferating cells |
CN1112943C (zh) | 1994-01-21 | 2003-07-02 | 粉剂注射疫苗股份有限公司 | 气体驱动的基因送递装置 |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
US5601820A (en) | 1994-07-07 | 1997-02-11 | Children's Hospital Of Philadelphia | Compositions and methods of making and using human full length TRK-B |
US5855579A (en) * | 1994-07-15 | 1999-01-05 | Smith & Nephew, Inc. | Cannulated modular intramedullary nail |
EP1181937A3 (en) | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5750340A (en) | 1995-04-07 | 1998-05-12 | University Of New Mexico | In situ hybridization solution and process |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
US5525510A (en) | 1995-06-02 | 1996-06-11 | Agracetus, Inc. | Coanda effect gene delivery instrument |
CA2223412C (en) | 1995-06-05 | 2010-03-23 | The University Of Washington | Method for prolonging the expression of a gene of interest using soluble ctla4 molecules |
US5993800A (en) * | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US5811406A (en) | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
US5668110A (en) | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
FR2737222B1 (fr) | 1995-07-24 | 1997-10-17 | Transgene Sa | Nouveaux vecteurs viraux et lignee pour la therapie genique |
WO1997004748A2 (en) | 1995-08-01 | 1997-02-13 | Advanced Therapies, Inc. | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
US5966560A (en) * | 1995-08-29 | 1999-10-12 | Minolta Co., Ltd. | Image forming apparatus with enhanced pretransfer erasing |
US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
JP2000500121A (ja) | 1995-09-27 | 2000-01-11 | エモリー・ユニバーシティー | 免疫系による生きた被移植細胞の破壊を阻止する方法 |
US7041634B2 (en) * | 1995-09-27 | 2006-05-09 | Emory University | Method of inhibiting immune system destruction of transplanted viable cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2248140C (en) * | 1996-03-04 | 2005-02-01 | Ronald P. Mischak | Assay and reagents for quantifying hbnp |
DK0892643T4 (da) * | 1996-03-20 | 2009-12-14 | Bristol Myers Squibb Co | Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved |
US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
US6110898A (en) | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
GB9619002D0 (en) | 1996-09-11 | 1996-10-23 | Oxford Biosciences Ltd | Particle delivery |
EP0987326A4 (en) | 1996-07-11 | 2002-11-06 | Takara Shuzo Co | METHOD FOR PERFORMING A DIRECTED MUTAGENESIS |
AU3980497A (en) | 1996-08-14 | 1998-03-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vector for polynucleotide vaccines |
US6211160B1 (en) | 1996-09-06 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6107477A (en) | 1996-09-26 | 2000-08-22 | Aurora Biosciences Corporation | Non-optimal Kozaks sequences |
JP2001503260A (ja) | 1996-10-23 | 2001-03-13 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 改良されたワクチン |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
PL334902A1 (en) | 1997-01-29 | 2000-03-27 | Cornell Res Foundation Inc | Repeatable local delivery of adenoviral vector in order to induce angiogenesis |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
US5837283A (en) | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
EA002087B1 (ru) | 1997-04-03 | 2001-12-24 | Электрофект Ас | Способ введения фармацевтических препаратов и нуклеиновых кислот в скелетную мышцу |
US6225082B1 (en) | 1997-05-09 | 2001-05-01 | Research Corporation Technologies, Inc. | Myelin basic protein MRNA transport and translation enhancer sequences |
ATE252596T1 (de) | 1997-06-06 | 2003-11-15 | Dynavax Tech Corp | Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon |
ATE256196T1 (de) | 1997-06-09 | 2003-12-15 | Genvec Inc | Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten |
DE19729058A1 (de) | 1997-07-08 | 1999-01-14 | Sika Ag | Verbundelement und Verfahren zu seiner Herstellung |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
AU8392898A (en) | 1997-07-14 | 1999-02-10 | Powerject Vaccines, Inc. | Method of dna vaccination using dna encoding antigen and encoding il6 |
WO1999008689A1 (en) | 1997-08-21 | 1999-02-25 | Powderject Vaccines, Inc. | Mucosal immunization using particle-mediated delivery techniques |
CA2304173A1 (en) | 1997-09-23 | 1999-04-01 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
AU2674299A (en) | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
US6087341A (en) | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
WO1999047558A2 (en) | 1998-03-19 | 1999-09-23 | Heska Corporation | T cell costimulatory proteins, sequences and uses thereof |
US6121236A (en) | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
BR9909789A (pt) | 1998-04-22 | 2000-12-26 | Genvec Inc | Método de purificação eficiente de adenovìrus |
BR9909918A (pt) | 1998-05-06 | 2000-12-26 | Upjohn Co | Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
US6800457B2 (en) * | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
US6225113B1 (en) | 1998-12-04 | 2001-05-01 | Genvec, Inc. | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
EP1141361B1 (en) | 1998-12-31 | 2010-04-21 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for packaging of alphavirus vectors |
PT1150918E (pt) | 1999-02-03 | 2005-01-31 | Biosante Pharmaceuticals Inc | Metodo de fabrico de particulas terapeuticas de fosfato de calcio |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
WO2001081609A2 (en) | 2000-03-22 | 2001-11-01 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
US6168941B1 (en) | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
CA2407050A1 (en) | 2000-04-25 | 2001-11-01 | Chiron Corporation | Alphavirus-based vectors for persistent infection |
US20020058039A1 (en) | 2000-04-27 | 2002-05-16 | Coyne Michael J. | Method of measuring the duration of adequate immune memory in companion animals |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
AR031699A1 (es) | 2000-05-26 | 2003-10-01 | Bristol Myers Squibb Co | Molecula mutante de ctla4 soluble que se enlaza a cd80 y/o cd86, molecula de acido nucleico que la codifica, vector y sistema vector que comprende a esta ultima, celula huesped que lo posee, metodo para producir una proteina mutante y dicha proteina, uso de la molecula mutante para preparar un medic |
AU2001268716A1 (en) | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel chimeric promoters |
US20050154189A1 (en) * | 2000-06-23 | 2005-07-14 | Maxygen Inc | Novel co-stimulatory molecules |
US7094875B2 (en) * | 2000-06-23 | 2006-08-22 | Maxygen, Inc. | Co-stimulatory polypeptides |
US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
CN1318086C (zh) * | 2000-07-03 | 2007-05-30 | 布里斯托尔-迈尔斯斯奎布公司 | 可溶性ctla4分子用于制备治疗风湿性疾病的药物组合物中的用途 |
EP1307551A2 (en) * | 2000-07-05 | 2003-05-07 | PHARMACIA & UPJOHN COMPANY | Human ion channels |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
MXPA03010568A (es) * | 2001-05-23 | 2005-03-07 | Squibb Bristol Myers Co | Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles. |
FR2843396B1 (fr) * | 2002-08-07 | 2005-04-15 | Bio Rad Pasteur | Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
CN100402660C (zh) * | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
SG144925A1 (en) * | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
US7731965B2 (en) * | 2005-02-17 | 2010-06-08 | Abbott Lab | Human ring specific BNP antibodies |
CN101141975B (zh) | 2005-03-25 | 2012-05-23 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
CA2603970A1 (en) | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
RU2506275C2 (ru) * | 2007-11-01 | 2014-02-10 | Астеллас Фарма Инк. | Иммуносупрессорные полипептиды и нуклеиновые кислоты |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
-
2008
- 2008-10-15 RU RU2010122053/10A patent/RU2506275C2/ru not_active IP Right Cessation
- 2008-10-15 PT PT13150320T patent/PT2612868T/pt unknown
- 2008-10-15 CN CN200880114532.0A patent/CN101998965B/zh active Active
- 2008-10-15 ES ES08844441T patent/ES2399088T3/es active Active
- 2008-10-15 JP JP2010532121A patent/JP5298134B2/ja active Active
- 2008-10-15 WO PCT/US2008/079981 patent/WO2009058564A2/en active Application Filing
- 2008-10-15 PT PT88444419T patent/PT2222697E/pt unknown
- 2008-10-15 AU AU2008319053A patent/AU2008319053B2/en not_active Ceased
- 2008-10-15 MX MX2010004883A patent/MX2010004883A/es active IP Right Grant
- 2008-10-15 KR KR1020107011711A patent/KR101383476B1/ko not_active IP Right Cessation
- 2008-10-15 US US12/251,960 patent/US7794718B2/en active Active
- 2008-10-15 PL PL13150320T patent/PL2612868T3/pl unknown
- 2008-10-15 EP EP11166011A patent/EP2385065A1/en not_active Withdrawn
- 2008-10-15 PL PL08844441T patent/PL2222697T3/pl unknown
- 2008-10-15 DK DK08844441.9T patent/DK2222697T3/da active
- 2008-10-15 CA CA2703263A patent/CA2703263C/en not_active Expired - Fee Related
- 2008-10-15 EP EP08844441A patent/EP2222697B1/en active Active
- 2008-10-15 EP EP13150320.3A patent/EP2612868B1/en active Active
- 2008-10-15 CN CN201310056076.1A patent/CN103172750B/zh active Active
- 2008-10-15 EP EP13150303.9A patent/EP2612867A1/en not_active Withdrawn
- 2008-10-15 ES ES13150320.3T patent/ES2688721T3/es active Active
- 2008-10-29 TW TW097141645A patent/TWI448473B/zh not_active IP Right Cessation
-
2010
- 2010-04-13 IL IL205036A patent/IL205036A/en not_active IP Right Cessation
- 2010-04-20 US US12/763,902 patent/US8071095B2/en active Active
- 2010-04-23 ZA ZA2010/02872A patent/ZA201002872B/en unknown
-
2011
- 2011-01-21 US US13/011,351 patent/US8445230B2/en active Active
- 2011-01-21 US US13/011,497 patent/US8318176B2/en active Active
- 2011-01-21 US US13/011,042 patent/US8268587B2/en active Active
- 2011-01-21 US US13/011,463 patent/US8283447B2/en active Active
- 2011-03-10 US US13/045,335 patent/US8491899B2/en active Active
- 2011-03-16 US US13/049,727 patent/US8496935B2/en active Active
-
2013
- 2013-02-21 CY CY20131100164T patent/CY1113713T1/el unknown
- 2013-03-05 HR HRP20130194AT patent/HRP20130194T1/hr unknown
- 2013-05-30 PH PH12013501101A patent/PH12013501101A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
HRP20200503T1 (hr) | Fuzijski proteini | |
IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
HRP20120246T1 (hr) | Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe | |
HRP20190918T1 (hr) | Ciljani terapeutski fuzijski proteini lizosomskog enzima i njihova upotreba | |
JP2011502479A5 (hr) | ||
HRP20161416T1 (hr) | Novi transportni konstrukti i transportne nosive konjugirane molekule | |
HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
RU2022102624A (ru) | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков | |
CN104072615B (zh) | 一种能阻断Tim-3信号通路的人Tim-3融合蛋白 | |
CN106913865A (zh) | 使用白细胞介素‑10治疗疾病和病症的方法 | |
EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
AU2022218633B2 (en) | R-spondin (RSPO) surrogate molecules | |
HUE035607T2 (en) | Targeted therapeutic agents | |
CN107001438A (zh) | 白细胞介素‑15组合物及其用途 | |
WO2008114149A3 (en) | Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains | |
WO2011036445A3 (en) | Polypeptides and uses thereof | |
HRP20180012T1 (hr) | Antikancerogeni fuzijski protein | |
JP2014523238A5 (hr) | ||
WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
CA2959045A1 (en) | Wnt signaling agonist molecules | |
RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
JP2014506450A5 (hr) |